Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - olanzapine, quantity: 10 mg - tablet, film coated - excipient ingredients: hypromellose; crospovidone; microcrystalline cellulose; lactose monohydrate; magnesium stearate; hyprolose; titanium dioxide; polysorbate 80; macrogol 400 - olanzapine tablets are indicated for the treatment of schizophrenia and related psychoses. ,olanzapine tablets alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,olanzapine tablets are also indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - olanzapine 10mg - orodispersible tablet - 10 mg - active: olanzapine 10mg excipient: aspartame colloidal silicon dioxide crospovidone avicel ce 15 (microcrystalline cellulose 85% and guar gum 15%) magnesium stearate mannitol microcrystalline cellulose pregelatinised maize starch sodium laurilsulfate - olanzapine tablets are indicated for the treatment of schizophrenia and related psychoses.

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - olanzapine 5mg - orodispersible tablet - 5 mg - active: olanzapine 5mg excipient: aspartame colloidal silicon dioxide crospovidone avicel ce 15 (microcrystalline cellulose 85% and guar gum 15%) magnesium stearate mannitol microcrystalline cellulose pregelatinised maize starch sodium laurilsulfate - olanzapine tablets are indicated for the treatment of schizophrenia and related psychoses.

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - olanzapine 10mg; olanzapine 10mg - film coated tablet - 10 mg - active: olanzapine 10mg excipient: crospovidone hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry blue 06b50833 active: olanzapine 10mg excipient: crospovidone hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white 06b580002 - olanzapine tablets are indicated for the treatment of schizophrenia and related psychoses.

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - olanzapine 2.5mg - film coated tablet - 2.5 mg - active: olanzapine 2.5mg excipient: crospovidone hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white oy-58900 - olanzapine tablets are indicated for the treatment of schizophrenia and related psychoses.

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - olanzapine 5mg; olanzapine 5mg - film coated tablet - 5 mg - active: olanzapine 5mg excipient: crospovidone hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry blue 06b50833 active: olanzapine 5mg excipient: crospovidone hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white 06b580002 - olanzapine tablets are indicated for the treatment of schizophrenia and related psychoses.

Izrael - angol - Ministry of Health

abic marketing ltd, israel - olanzapine - film coated tablets - olanzapine 5 mg - olanzapine - acute and maintenance treatment of schizophrenia. olanzapine teva® is indicated for the management of the manifestations of psychotic disorders. olanzapine teva® is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.prevention of recurrence in bipolar disorder: in patients whose manic episode has responded to olanzapine treatment olanzapine teva® is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder. the combination of olanzapine teva® with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

Európai Unió - angol - EMA (European Medicines Agency)

apotex europe bv - olanzapine - schizophrenia; bipolar disorder - psycholeptics - olanzapine is indicated for the treatment of schizophrenia.olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.olanzapine is indicated for the treatment of moderate to severe manic episode.in patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.

Egyesült Államok - angol - NLM (National Library of Medicine)

sandoz inc - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr), fluoxetine hydrochloride (unii: i9w7n6b1kj) (fluoxetine - unii:01k63sup8d) - olanzapine 3 mg - olanzapine and fluoxetine capsules are indicated for the treatment of: the use of maois intended to treat psychiatric disorders with olanzapine and fluoxetine hydrochloride or within 5 weeks of stopping treatment with olanzapine and fluoxetine hydrochloride is contraindicated because of an increased risk of serotonin syndrome. the use of olanzapine and fluoxetine hydrochloride within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration (2.4) and warnings and precautions ( 5.6 )] . starting olanzapine and fluoxetine hydrochloride in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see dosage and administration (2.5) and warnings and precautions ( 5.6 )] . pimozide and thioridazine prolong the qt interval. olanzapine and fluoxetine hydrochloride can increase the levels of pimozide and thioridazine through inhibition of cyp2d6.

Egyesült Államok - angol - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine 5 mg - olanzapine orally disintegrating tablets are indicated for the treatment of schizophrenia. efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. in adolescent patients with schizophrenia (ages 13 to 17), efficacy was established in one 6-week trial [see clinical studies (14.1)]. when deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see warnings and precautions (5.5)]. monotherapy — olanzapine orally disintegrating tablets are indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder and maintenance treatment of bipolar i disorder. efficacy was established in three clin